Chandler Park, Kentucky Medical Oncologist Representative at National Comprehensive Cancer Network, Oncologist at Norton Healthcare, and Kentucky Physician Representative of ASCO State Executive Council, shared a post on LinkedIn about a paper by Neal D. Shore et al. published in NEJM:
“Congratulations to Dr. Stephen Freedland, Dr Neal Shore, and the entire EMBARK study investigators. NEJM has just released.
We had an inspiring evening celebrating this practice-changing study to help our prostate cancer patients.
- Fixed-duration therapy to decrease treatment side effects
- Significant improvement in Overall Survival
Over dinner, we reflected on more than a decade of dedication by the EMBARK study team that led to these truly practice-changing results at ESMO25.
Honored to celebrate this milestone with great friends and colleagues.”
Title: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
Authors: Neal D. Shore, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T. Gotto, Christopher M. Pieczonka, Gabriel P. Haas, Choung-Soo Kim, Miguel Ramirez-Backhaus, Antti Rannikko, Matko Kalac, Swetha Sridharan, Matt Rosales, Yiyun Tang, Ronald F. Tutrone, Jr., Balaji Venugopal, Arnauld Villers, Henry H. Woo, Fong Wang, and Stephen J. Freedland.
You can read the Full Article in NEJM.
More posts featuring Chandler Park.